Iconic Labs PLC
28 August 2026
Iconic Labs PLC
("Iconic" or the "Company")
Total Voting Rights & Admission to Trading
Total Voting Rights
In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 28 August 2026, the Company's issued share capital consists of 16,780,647 Ordinary Shares of £0.0001, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 16,780,647.
The above figure of 16,780,647 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Admission to Trading
In accordance with the Financial Conduct Authority's Prospectus Rules, Iconic announces that 370,370 new Ordinary Shares in the Company were admitted to trading on the Main Market of the London Stock Exchange on 3 July 2026 and 370,370 new Ordinary Shares in the Company were admitted to trading on the Main Market of the London Stock Exchange on 4 August 2026.
|
1) |
Name and LEI |
Iconic Labs PLC 213800YCXZV6RSHGGT04 |
|
2) |
Regulated Market |
London Stock Exchange - Main Market |
|
3) |
Name, type and ISIN |
Ordinary Shares of £0.0001 each ISIN: GB00BRBJ3P08 |
|
4) |
Number of further securities issued and admitted |
740,740 |
|
5) |
Total number of securities in issue following admission |
16,780,647 |
|
6) |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
7) |
Dates of Admission |
3 July 2026 and 4 August 2026 |
|
8) |
Prospectus Information |
N/A |
--ENDS--
For any further information or enquiries please contact:
|
|||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.